# Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

> **NCT05085496** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 12 (estimated)

## Conditions studied

- Locally Advanced Skin Squamous Cell Carcinoma
- Resectable Skin Squamous Cell Carcinoma
- Unresectable Skin Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT05085496
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-19
- **Primary completion:** 2027-09-10
- **Final completion:** 2027-09-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05085496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05085496, "Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05085496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*